Department of Cardiology, Centre for Heart Rhythm Disorders, South Australian Health and Medical Research Institute, University of Adelaide and Royal Adelaide Hospital, Adelaide, SA, 5000, Australia.
Herzzentrum Dresden- Abteilung für Invasive Elektrophysiologie, Dresden, Germany.
BMC Cardiovasc Disord. 2019 May 31;19(1):132. doi: 10.1186/s12872-019-1106-3.
Historically, the majority of insertable cardiac monitor (ICM) procedures were performed in the cardiac catheterization (cath) lab, electrophysiology (EP) lab, or operating room (OR). The miniaturization of ICMs allows the procedure to be relocated within the hospital without compromising patient safety. We sought to estimate the rate of untoward events associated with procedures performed within the hospital but outside the traditional settings and to characterize resource utilization, procedure time intervals, and physician experience.
The Reveal LINQ in-Office 2 (RIO 2) International study was a single arm, multicenter, prospective study. Patients indicated for an ICM and willing to undergo device insertion outside the cath/EP lab or OR were eligible and followed for 90 days after insertion.
A total of 191 patients (45.5% female aged 63.8 ± 26.9 years) underwent successful Reveal LINQ ICM insertion at 17 centers in Europe, Canada and Australia. The median total visit duration was 106 min (interquartile range [IQR]: 55-61). Patient preparation and patient education accounted for 10 min (IQR: 5-20) and 10 min (IQR: 8-15) of total visit duration, respectively. Preparation and education occurred in the procedure room for 90.6 and 60.2% of patients, respectively. There were no untoward events (0.0, 95% CI: 0.0-2.1%) though four patients presented with procedure-related adverse events that did not require invasive intervention. Physicians rated procedure location as convenient or very convenient.
The Reveal LINQ™ ICM insertion can be safely and efficiently performed in the hospital outside the cath/EP lab or OR.
ClinicalTrials.gov identifier NCT02412488 ; registered on April 9, 2015.
历史上,大多数可插入式心脏监测器(ICM)程序都是在心脏导管插入术(心导管)实验室、电生理(EP)实验室或手术室(OR)进行的。ICM 的小型化使得该程序可以在不影响患者安全的情况下在医院内重新定位。我们旨在估计与在传统设置之外的医院内进行的程序相关的不良事件的发生率,并描述资源利用、程序时间间隔和医生经验。
Reveal LINQ in-Office 2(RIO 2)国际研究是一项单臂、多中心、前瞻性研究。符合指征并愿意在心脏导管室/电生理室或手术室以外进行设备插入的患者有资格入组,并在插入后 90 天内进行随访。
共有 191 名患者(45.5%为女性,年龄 63.8±26.9 岁)在欧洲、加拿大和澳大利亚的 17 个中心成功进行了 Reveal LINQ ICM 插入。中位总就诊时间为 106 分钟(四分位距[IQR]:55-61)。患者准备和患者教育分别占总就诊时间的 10 分钟(IQR:5-20)和 10 分钟(IQR:8-15)。准备和教育分别在 90.6%和 60.2%的患者的程序室中进行。虽然有 4 名患者出现了不需要侵入性干预的与程序相关的不良事件,但没有不良事件(0.0,95%CI:0.0-2.1%)。医生将程序位置评为方便或非常方便。
Reveal LINQ ICM 插入可以安全、有效地在心脏导管室/电生理室或手术室以外的医院进行。
ClinicalTrials.gov 标识符 NCT02412488;注册于 2015 年 4 月 9 日。